home / stock / mrns / mrns quote
Last: | $1.51 |
---|---|
Change Percent: | -3.45% |
Open: | $1.5 |
Close: | $1.51 |
High: | $1.65 |
Low: | $1.48 |
Volume: | 1,603,749 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.51 | $1.5 | $1.51 | $1.65 | $1.48 | 1,603,749 | 05-03-2024 |
$1.45 | $1.49 | $1.45 | $1.53 | $1.45 | 989,641 | 05-02-2024 |
$1.47 | $1.4 | $1.47 | $1.52 | $1.4 | 2,278,646 | 05-01-2024 |
$1.41 | $1.42 | $1.41 | $1.43 | $1.39 | 1,365,206 | 04-30-2024 |
$1.4 | $1.41 | $1.4 | $1.44 | $1.39 | 930,317 | 04-29-2024 |
$1.405 | $1.42 | $1.405 | $1.455 | $1.38 | 1,136,344 | 04-26-2024 |
$1.42 | $1.4 | $1.42 | $1.44 | $1.37 | 1,350,534 | 04-25-2024 |
$1.44 | $1.44 | $1.44 | $1.46 | $1.39 | 1,507,132 | 04-24-2024 |
$1.44 | $1.45 | $1.44 | $1.56 | $1.395 | 2,860,284 | 04-23-2024 |
$1.475 | $1.38 | $1.475 | $1.5 | $1.35 | 3,257,216 | 04-22-2024 |
$1.38 | $1.41 | $1.38 | $1.55 | $1.37 | 2,618,548 | 04-19-2024 |
$1.41 | $1.46 | $1.41 | $1.53 | $1.17 | 4,841,039 | 04-18-2024 |
$1.44 | $1.23 | $1.44 | $1.54 | $1.16 | 10,367,883 | 04-17-2024 |
$1.2 | $1.32 | $1.2 | $1.65 | $1.11 | 22,196,654 | 04-16-2024 |
$1.3 | $1.85 | $1.3 | $1.95 | $1.25 | 35,571,117 | 04-15-2024 |
$7.52 | $7.87 | $7.52 | $7.99 | $7.4 | 623,997 | 04-12-2024 |
$7.92 | $8.17 | $7.92 | $8.26 | $7.9 | 434,207 | 04-11-2024 |
$8.09 | $8.16 | $8.09 | $8.28 | $7.88 | 671,287 | 04-10-2024 |
$8.38 | $8.18 | $8.38 | $8.45 | $8.04 | 634,519 | 04-09-2024 |
$8.2 | $7.85 | $8.2 | $8.26 | $7.4201 | 688,720 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capit...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024. ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...